Vara Research Siemens Healthineers Pre FY 2021 Earnings Estimates as of October 26th, 2021 | ||||
Q4 2020 | FY 2020 | Q4 2021 E | FY 2021 E | |
Revenue | ||||
- Number of Estimates | 14 | 14 | ||
- Highest | 5,168 | 18,001 | ||
- Consensus | 3,876 | 14,460 | 5,046 | 17,879 |
- Median | 5,050 | 17,883 | ||
- Lowest | 4,841 | 17,674 | ||
Comparable growth rate (in %) | ||||
- Number of Estimates | 12 | 13 | ||
- Highest | 12.6 | 19.7 | ||
- Consensus | -2.0 | -0.2 | 10.6 | 18.3 |
- Median | 10.9 | 18.2 | ||
- Lowest | 8.4 | 17.0 | ||
R&D Expenses | ||||
- Number of Estimates | 13 | 13 | ||
- Highest | -343 | -1,406 | ||
- Consensus | -340 | -1,342 | -454 | -1,517 |
- Median | -423 | -1,486 | ||
- Lowest | -602 | -1,665 | ||
D&A | ||||
- Number of Estimates | 14 | 14 | ||
- Highest | -224 | -978 | ||
- Consensus | -215 | -815 | -396 | -1,150 |
- Median | -394 | -1,148 | ||
- Lowest | -587 | -1,341 | ||
Adjusted EBIT (SHS definition) | ||||
- Number of Estimates | 14 | 14 | ||
- Highest | 982 | 3,331 | ||
- Consensus | 631 | 2,248 | 898 | 3,247 |
- Median | 905 | 3,254 | ||
- Lowest | 798 | 3,147 | ||
Amortization of intangible assets acquired in business combinations | ||||
- Number of Estimates | 13 | 13 | ||
- Highest | -109 | -350 | ||
- Consensus | -39 | -168 | -187 | -428 |
- Median | -179 | -420 | ||
- Lowest | -229 | -470 | ||
Severance charges | ||||
- Number of Estimates | 13 | 13 | ||
- Highest | -1 | -50 | ||
- Consensus | -22 | -65 | -20 | -69 |
- Median | -16 | -65 | ||
- Lowest | -63 | -112 | ||
Acquisition-related costs | ||||
- Number of Estimates | 12 | 12 | ||
- Highest | 9 | -100 | ||
- Consensus | -11 | -34 | -83 | -192 |
- Median | -74 | -183 | ||
- Lowest | -164 | -273 | ||
Financial income, net | ||||
- Number of Estimates | 14 | 14 | ||
- Highest | 47 | -95 | ||
- Consensus | -10 | -27 | -25 | -167 |
- Median | -21 | -163 | ||
- Lowest | -95 | -237 | ||
Tax expense | ||||
- Number of Estimates | 14 | 14 | ||
- Highest | -111 | -640 | ||
- Consensus | -118 | -532 | -157 | -686 |
- Median | -167 | -696 | ||
- Lowest | -194 | -723 | ||
Minorities | ||||
- Number of Estimates | 12 | 12 | ||
- Highest | 2 | -12 | ||
- Consensus | -4 | -12 | -4 | -18 |
- Median | -4 | -18 | ||
- Lowest | -6 | -20 | ||
Reported net income attr. to shareholder | ||||
- Number of Estimates | 14 | 14 | ||
- Highest | 543 | 1,808 | ||
- Consensus | 428 | 1,411 | 417 | 1,682 |
- Median | 426 | 1,691 | ||
- Lowest | 295 | 1,560 | ||
Number of outstanding shares | ||||
- Number of Estimates | 14 | 14 | ||
- Highest | 1,128 | 1,108 | ||
- Consensus | 1,011 | 1,002 | 1,127 | 1,102 |
- Median | 1,128 | 1,102 | ||
- Lowest | 1,124 | 1,100 | ||
EPS reported (in EUR) | ||||
- Number of Estimates | 14 | 14 | ||
- Highest | 0.48 | 1.64 | ||
- Consensus | 0.42 | 1.41 | 0.37 | 1.53 |
- Median | 0.37 | 1.53 | ||
- Lowest | 0.26 | 1.42 | ||
Adjusted EPS (in EUR) | ||||
- Number of Estimates | 13 | 13 | ||
- Highest | 0.61 | 2.10 | ||
- Consensus | 0.48 | 1.61 | 0.56 | 2.05 |
- Median | 0.56 | 2.05 | ||
- Lowest | 0.51 | 2.00 | ||
DPS (in EUR) | ||||
- Number of Estimates | 0 | 13 | ||
- Highest | - | 1.22 | ||
- Consensus | - | 0.80 | - | 0.89 |
- Median | - | 0.88 | ||
- Lowest | - | 0.76 | ||
Segment estimates | ||||
Imaging, Revenue | ||||
- Number of Estimates | 14 | 14 | ||
- Highest | 2,746 | 9,809 | ||
- Consensus | 2,447 | 9,090 | 2,645 | 9,708 |
- Median | 2,663 | 9,726 | ||
- Lowest | 2,387 | 9,450 | ||
Imaging, Comparable growth rate (in %) | ||||
- Number of Estimates | 11 | 13 | ||
- Highest | 10.8 | 11.9 | ||
- Consensus | -1.7 | 1.6 | 9.1 | 10.7 |
- Median | 9.0 | 10.7 | ||
- Lowest | 7.0 | 10.0 | ||
Imaging, Adj. EBIT (SHS definition) | ||||
- Number of Estimates | 14 | 14 | ||
- Highest | 665 | 2,136 | ||
- Consensus | 551 | 1,916 | 642 | 2,113 |
- Median | 647 | 2,118 | ||
- Lowest | 597 | 2,068 | ||
Diagnostics, Revenue | ||||
- Number of Estimates | 14 | 14 | ||
- Highest | 1,267 | 5,407 | ||
- Consensus | 1,038 | 3,924 | 1,162 | 5,302 |
- Median | 1,182 | 5,322 | ||
- Lowest | 1,059 | 5,199 | ||
Diagnostics, Comparable growth rate (in %) | ||||
- Number of Estimates | 11 | 13 | ||
- Highest | 18.1 | 42.0 | ||
- Consensus | -1.0 | -4.2 | 12.5 | 39.3 |
- Median | 15.0 | 40.4 | ||
- Lowest | 5.0 | 35.0 | ||
Diagnostics, Adj. EBIT (SHS definition) | ||||
- Number of Estimates | 14 | 14 | ||
- Highest | 140 | 768 | ||
- Consensus | 8 | 74 | 79 | 707 |
- Median | 80 | 708 | ||
- Lowest | 42 | 670 | ||
therein revenue from rapid COVID-19 antigen test | ||||
- Number of Estimates | 5 | 5 | ||
- Highest | 130 | 1,050 | ||
- Consensus | - | - | 104 | 1,024 |
- Median | 100 | 1,020 | ||
- Lowest | 80 | 1,000 | ||
therein adj. EBIT from rapid COVID-19 antigen tests | ||||
- Number of Estimates | 0 | 1 | ||
- Highest | - | 434.0 | ||
- Consensus | - | - | - | 434.0 |
- Median | - | 434.0 | ||
- Lowest | - | 434.0 | ||
Advanced Therapies, Revenue | ||||
- Number of Estimates | 14 | 14 | ||
- Highest | 493 | 1,710 | ||
- Consensus | 432 | 1,628 | 481 | 1,698 |
- Median | 484 | 1,701 | ||
- Lowest | 449 | 1,666 | ||
Advanced Therapies, Comparable growth rate (in %) | ||||
- Number of Estimates | 11 | 13 | ||
- Highest | 14.5 | 9.0 | ||
- Consensus | -6.4 | 1.1 | 11.7 | 7.9 |
- Median | 12.1 | 8.0 | ||
- Lowest | 5.0 | 6.1 | ||
Advanced Therapies, Adj. EBIT (SHS definition) | ||||
- Number of Estimates | 14 | 14 | ||
- Highest | 96.0 | 269.0 | ||
- Consensus | 83.0 | 308.0 | 80.5 | 253.5 |
- Median | 80.6 | 253.6 | ||
- Lowest | 57.0 | 230.0 | ||
Varian, Revenue | ||||
- Number of Estimates | 14 | 14 | ||
- Highest | 809 | 1,400 | ||
- Consensus | - | - | 767 | 1,358 |
- Median | 766 | 1,357 | ||
- Lowest | 671 | 1,262 | ||
Varian, Comparable growth rate (in % | ||||
- Number of Estimates | 0 | |||
- Highest | - | |||
- Consensus | - | - | - | - |
- Median | - | |||
- Lowest | - | |||
Varian, Adj. EBIT (SHS definition) | ||||
- Number of Estimates | 14 | 14 | ||
- Highest | 129.0 | 227.0 | ||
- Consensus | - | - | 118.8 | 216.8 |
- Median | 117.9 | 215.9 | ||
- Lowest | 107.0 | 205.0 | ||
Others | ||||
Economic net debt (SHS definition) | ||||
- Number of Estimates | 0 | 15 | ||
- Highest | - | 15,845 | ||
- Consensus | - | 2,605 | - | 13,170 |
- Median | - | 12,957 | ||
- Lowest | - | 11,570 | ||
Change in operating net working capital | ||||
- Number of Estimates | 0 | 10 | ||
- Highest | - | 897 | ||
- Consensus | - | -148 | - | -157 |
- Median | - | -14 | ||
- Lowest | - | -1,096 | ||
Capex | ||||
- Number of Estimates | 0 | 13 | ||
- Highest | - | -617 | ||
- Consensus | - | -557 | - | -748 |
- Median | - | -693 | ||
- Lowest | - | -1,202 | ||
Free Cash Flow (SHS definition) | ||||
- Number of Estimates | 0 | 13 | ||
- Highest | - | 3,984 | ||
- Consensus | - | 1,371 | - | 2,064 |
- Median | - | 1,986 | ||
- Lowest | - | 1,208 | ||
USD assumption | ||||
- Number of Estimates | 0 | 5 | ||
- Highest | - | 1.20 | ||
- Consensus | - | 1.20 | ||
- Median | - | 1.20 | ||
- Lowest | - | 1.19 | ||
WACC used for DCF | ||||
- Number of Estimates | 0 | 5 | ||
- Highest | - | 8.0 | ||
- Consensus | - | 6.7 | ||
- Median | - | 7.0 | ||
- Lowest | - | 5.0 | ||
This report was prepared by Vara Research GmbH for informational purposes only and is not intended to provide investment advice. It is based on an evaluation of past and an estimation of future earnings and performance of the relevant company by various market analysts. Owing to their subjective character, such estimates and forecasts cannot be independently verified. Despite careful review, Vara Research GmbH cannot provide any guarantee, assurance or warranty as to completeness or accuracy; responsibility or liability is therefore excluded. | This document has been issued by Vara Research GmbH for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. The company did not participate in the compilation of the estimates and it does not endorse them. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Vara Research GmbH gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. | This document has been issued by Vara Research GmbH for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. The company did not participate in the compilation of the estimates and it does not endorse them. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Vara Research GmbH gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. | This document has been issued by Vara Research GmbH for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. The company did not participate in the compilation of the estimates and it does not endorse them. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Vara Research GmbH gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. | This document has been issued by Vara Research GmbH for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. The company did not participate in the compilation of the estimates and it does not endorse them. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Vara Research GmbH gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. |
Attachments
- Original document
- Permalink
Disclaimer
Siemens Healthineers AG published this content on 28 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 October 2021 07:30:06 UTC.